Published in Med Hypotheses on January 04, 2006
Enhanced case detection and improved diagnosis of PKDL in a Kala-azar-endemic area of Bangladesh. PLoS Negl Trop Dis (2010) 1.51
Post kala-azar dermal leishmaniasis: an unresolved mystery. Trends Parasitol (2014) 1.04
Post-Kala-Azar Dermal Leishmaniasis: A Paradigm of Paradoxical Immune Reconstitution Syndrome in Non-HIV/AIDS Patients. J Trop Med (2013) 0.87
A review of visceral leishmaniasis during the conflict in South Sudan and the consequences for East African countries. Parasit Vectors (2016) 0.81
Misdiagnosis and mistreatment of post-kala-azar dermal leishmaniasis. Case Rep Med (2013) 0.78
Treatment-based strategy for the management of post-kala-azar dermal leishmaniasis patients in the Sudan. J Trop Med (2013) 0.78
The immunology of post-kala-azar dermal leishmaniasis (PKDL). Parasit Vectors (2016) 0.78
Post-kala-azar dermal leishmaniasis. Lancet Infect Dis (2003) 3.63
A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein-1 in an area of unstable malaria in Sudan. J Immunol (1998) 2.94
Detection of antibodies to variant antigens on Plasmodium falciparum-infected erythrocytes by flow cytometry. Cytometry (1999) 2.87
Detection of very low level Plasmodium falciparum infections using the nested polymerase chain reaction and a reassessment of the epidemiology of unstable malaria in Sudan. Am J Trop Med Hyg (1996) 2.72
Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. Infect Immun (1999) 2.16
Antibodies to variable Plasmodium falciparum-infected erythrocyte surface antigens are associated with protection from novel malaria infections. Immunol Lett (2000) 1.89
Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet (2000) 1.86
The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. J Antimicrob Chemother (1999) 1.77
Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis (2000) 1.76
Antibodies to variant antigens on the surfaces of infected erythrocytes are associated with protection from malaria in Ghanaian children. Infect Immun (2001) 1.69
Morphology of the spleen and lymph nodes in fatal visceral leishmaniasis. Immunology (1977) 1.68
Anti-phospholipid antibodies in patients with Plasmodium falciparum malaria. Immunology (1993) 1.64
Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine (2009) 1.59
Nine-year longitudinal study of antibodies to variant antigens on the surface of Plasmodium falciparum-infected erythrocytes. Infect Immun (1999) 1.59
Increased plasma concentrations of sICAM-1, sVCAM-1 and sELAM-1 in patients with Plasmodium falciparum or P. vivax malaria and association with disease severity. Immunology (1994) 1.55
The epidemiology of febrile malaria episodes in an area of unstable and seasonal transmission. Trans R Soc Trop Med Hyg (2001) 1.53
Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect Immun (1993) 1.50
Seasonal changes in the Plasmodium falciparum population in individuals and their relationship to clinical malaria: a longitudinal study in a Sudanese village. Parasitology (1998) 1.48
Rapid reemergence of T cells into peripheral circulation following treatment of severe and uncomplicated Plasmodium falciparum malaria. Infect Immun (1997) 1.45
Transient depletion of T cells with high LFA-1 expression from peripheral circulation during acute Plasmodium falciparum malaria. Eur J Immunol (1991) 1.44
Differential patterns of human immunoglobulin G subclass responses to distinct regions of a single protein, the merozoite surface protein 1 of Plasmodium falciparum. Infect Immun (2001) 1.44
Evidence of endothelial inflammation, T cell activation, and T cell reallocation in uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg (1994) 1.42
Random amplified polymorphic DNA for the differentiation of Leishmania donovani isolates from Sudan. Trans R Soc Trop Med Hyg (1996) 1.41
High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. Clin Exp Immunol (1998) 1.40
Granulomatous mammary disease: ten years' experience with fine needle aspiration cytology. Int J Tuberc Lung Dis (2003) 1.35
The perception and practice of traditional medicine in the treatment of cancers and inflammations by the Hausa and Fulani tribes of Northern Nigeria. J Ethnopharmacol (2007) 1.34
A new portable device for automatic controlled-gradient cryopreservation of blood mononuclear cells. J Immunol Methods (1993) 1.29
Increased plasma levels of soluble ICAM-1 and ELAM-1 (E-selectin) during acute Plasmodium falciparum malaria. Immunol Lett (1993) 1.25
Chronic Plasmodium falciparum infections in an area of low intensity malaria transmission in the Sudan. Parasitology (2000) 1.25
Genetic characterization of wild-type measles viruses circulating in suburban Khartoum, 1997-2000. J Gen Virol (2002) 1.24
Eleven years of malaria surveillance in a Sudanese village highlights unexpected variation in individual disease susceptibility and outbreak severity. Parasitology (2004) 1.23
Genetics and visceral leishmaniasis: of mice and man. Parasite Immunol (2009) 1.21
Overlapping antigenic repertoires of variant antigens expressed on the surface of erythrocytes infected by Plasmodium falciparum. Parasitology (1999) 1.21
Kala-azar in a high transmission focus: an ethnic and geographic dimension. Am J Trop Med Hyg (1999) 1.19
The novel oxygenated chalcone, 2,4-dimethoxy-4'-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelii in vivo. J Infect Dis (1997) 1.18
Surface ultrastructure of the human placental villi and sites of contact with maternal red blood cells. Arch Gynecol (1982) 1.18
The roles of the pfcrt 76T and pfmdr1 86Y mutations, immunity and the initial level of parasitaemia, in predicting the outcome of chloroquine treatment in two areas with different transmission intensities. Ann Trop Med Parasitol (2005) 1.17
Inhibition of fumarate reductase in Leishmania major and L. donovani by chalcones. Antimicrob Agents Chemother (2001) 1.17
Licochalcone A, a new antimalarial agent, inhibits in vitro growth of the human malaria parasite Plasmodium falciparum and protects mice from P. yoelii infection. Antimicrob Agents Chemother (1994) 1.16
Dichotomy of the human T cell response to Leishmania antigens. I. Th1-like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis. Clin Exp Immunol (1994) 1.16
Loss of cellular immune reactivity during acute Plasmodium falciparum malaria. FEMS Microbiol Immunol (1991) 1.15
Seasonal variation in agglutination of Plasmodium falciparum-infected erythrocytes. Am J Trop Med Hyg (1998) 1.15
Epidemiology and clinical manifestations of Leishmania donovani infection in two villages in an endemic area in eastern Sudan. Trop Med Int Health (2002) 1.15
Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of Leishmania. Antimicrob Agents Chemother (1993) 1.14
Suppression of parasite-specific response in Plasmodium falciparum malaria. A longitudinal study of blood mononuclear cell proliferation and subset composition. Scand J Immunol (1986) 1.14
Diagnosis of tuberculous lymphadenitis by FNAC, microbiological methods and PCR: a comparative study. Cytopathology (2004) 1.13
Antimony-resistant Leishmania donovaniin eastern Sudan: incidence and in vitro correlation. East Mediterr Health J (2003) 1.13
Recognition of Leishmania antigens by T lymphocytes from nonexposed individuals. Infect Immun (1992) 1.13
Interferon-gamma- and tumour necrosis factor-alpha-producing cells in humans who are immune to cutaneous leishmaniasis. Scand J Immunol (1999) 1.11
Lymphocyte response to purified Plasmodium falciparum antigens during and after malaria. Acta Trop (1986) 1.11
Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani. Antimicrob Agents Chemother (1994) 1.11
The contrasting roles of CD4+ T cells in intracellular infections in humans: leishmaniasis as an example. Immunol Today (1996) 1.10
Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile. J Pathol (1999) 1.10
Soluble Plasmodium falciparum antigens contain carbohydrate moieties important for immune reactivity. J Clin Microbiol (1987) 1.09
Leishmania resistant to sodium stibogluconate: drug-associated macrophage-dependent killing. Parasitol Res (1994) 1.09
The natural history of Sudanese post-kala-azar dermal leishmaniasis: clinical, immunological and prognostic features. Ann Trop Med Parasitol (2002) 1.09
Dichotomy of the human T cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients. Clin Exp Immunol (1994) 1.08
Evaluation of the polymerase chain reaction in the diagnosis of cutaneous leishmaniasis due to Leishmania major: a comparison with direct microscopy of smears and sections from lesions. Trans R Soc Trop Med Hyg (1996) 1.07
Calcium deposition on the maternal surface of the human placenta: a scanning electron microscopic study. Arch Gynecol (1984) 1.07
Clinical pattern of severe Plasmodium falciparum malaria in Sudan in an area characterized by seasonal and unstable malaria transmission. Trans R Soc Trop Med Hyg (2005) 1.07
Genetic susceptibility to visceral leishmaniasis in The Sudan: linkage and association with IL4 and IFNGR1. Genes Immun (2003) 1.06
High proportion of subclinical Plasmodium falciparum infections in an area of seasonal and unstable malaria in Sudan. Am J Trop Med Hyg (1995) 1.04
Specific T-cell recognition of the merozoite proteins rhoptry-associated protein 1 and erythrocyte-binding antigen 1 of Plasmodium falciparum. Infect Immun (1993) 1.04
Characterization of the local and systemic immune responses in patients with cutaneous leishmaniasis due to Leishmania major. Clin Immunol (1999) 1.03
A longitudinal study of human antibody responses to Plasmodium falciparum rhoptry-associated protein 1 in a region of seasonal and unstable malaria transmission. Infect Immun (1999) 1.03
Diagnosis of visceral leishmaniasis by the polymerase chain reaction using blood, bone marrow and lymph node samples from patients from the Sudan. Trop Med Int Health (1997) 1.02
Proliferation induced by Plasmodium falciparum antigen and interleukin-2 production by lymphocytes isolated from malaria-immune individuals. Infect Immun (1986) 1.02
Specific proliferative response of human lymphocytes to purified soluble antigens from Plasmodium falciparum in vitro cultures and to antigens from malaria patients' sera. Clin Exp Immunol (1985) 1.01
Activation of human T lymphocytes by Leishmania lipophosphoglycan. Scand J Immunol (1991) 1.01
Cell-mediated immune responses to Plasmodium falciparum purified soluble antigens in sickle-cell trait subjects. Immunol Lett (1990) 1.00
Cellular and humoral immune responses in a population from the Baringo District, Kenya to Leishmania promastigote lipophosphoglycan. Am J Trop Med Hyg (1992) 1.00
T-cell response in human leishmaniasis. Immunol Lett (1999) 1.00
Leishmania-specific T cells expressing interferon-gamma (IFN-gamma) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. Clin Exp Immunol (1999) 1.00
The development of post-kala-azar dermal leishmaniasis (PKDL) is associated with acquisition of Leishmania reactivity by peripheral blood mononuclear cells (PBMC). Clin Exp Immunol (2000) 0.99
Treatment of visceral leishmaniasis with sodium stibogluconate in Sudan: management of those who do not respond. Ann Trop Med Parasitol (1998) 0.99
Changing pattern for extremity amputations in University of Maiduguri Teaching Hospital, Nigeria. Niger J Med (2007) 0.99
Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guérrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers. Trans R Soc Trop Med Hyg (2004) 0.98
Antibody responses to Rhoptry-Associated Protein-1 (RAP-1) of Plasmodium falciparum parasites in humans from areas of different malaria endemicity. Parasite Immunol (1997) 0.98
Serodiagnosis of Leishmania donovani infections: assessment of enzyme-linked immunosorbent assays using recombinant L. donovani gene B protein (GBP) and a peptide sequence of L. donovani GBP. Trans R Soc Trop Med Hyg (1999) 0.96
Post kala-azar ocular leishmaniasis. Trans R Soc Trop Med Hyg (1998) 0.96
Increased plasma levels of soluble IL-2R are associated with severe Plasmodium falciparum malaria. Clin Exp Immunol (1994) 0.95
Antibody reactivity to conserved linear epitopes of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). Immunol Lett (1998) 0.94
Humoral and cellular immune responses to synthetic peptides of the Leishmania donovani kinetoplastid membrane protein-11. Scand J Immunol (1998) 0.94
Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL). Ann Trop Med Parasitol (2005) 0.93